Skip to main content
Caplight Logo









Flomics Biotech

Flomics Biotech

Private
BarcelonaHealthcare & Life Scienceshttps://www.flomics.com/

Last Round

Crowdfunding

Jul 12, 2024

Est. Valuation

$10.67M

Total Funding Raised

$3.18M

Company Overview

Flomics Biotech is a biotechnology company that develops liquid biopsy tests for the early detection of cancer and other complex diseases using cell-free RNA and artificial intelligence.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

liquid biopsycell-free RNAcfRNAcancer blood testearly cancer detectionNGSnext-generation sequencingbioinformaticsprecision medicinediagnostic screeningbiomarker discoverymedical AICROcontract research organizationoncology diagnosticsmulti-cancer screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flomics Biotech Comparables

Compare Flomics Biotech with similar companies based on industry and business-model similarity.

Flomics Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Resero Bio, Inc.
83%
MultiplAI Health
77%
Elypta
77%

Flomics Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingJul 12, 2024
SeedMar 6, 2024
SeedMar 31, 2022

Key People

Founding team and executive leadership

André Guedes

COO & Co-founder

Founding Team

João Curado

Co-Founder and CEO

Founding Team

Flomics Biotech Investors

Notable investors and investment history

Flomics Biotech investors
InvestorRounds
Decelera VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 14, 2026

    Grew 25% QoQ, from 16 to 20 employees.

  • Nov 7, 2025

    Monthly visitors grew 96% MoM.

Flomics Biotech Filings

Explore SEC and related filing metadata, where available.

Flomics Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Flomics Biotech's valuation, stock price, and market status.

Is Flomics Biotech a public or private company?

Flomics Biotech is a private company.

What is the current stock price of Flomics Biotech?

Flomics Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Flomics Biotech worth (valuation)?

Flomics Biotech's valuation is estimated at $10.7M based on funding round data.

Can I buy Flomics Biotech stock?

Flomics Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Flomics Biotech's last funding round?

Flomics Biotech's most recent funding round was Crowdfunding on July 12, 2024.

Who are the main investors in Flomics Biotech?

Key investors in Flomics Biotech include Decelera Ventures.

Will Flomics Biotech IPO soon?

No public IPO plans have been announced for Flomics Biotech.

How can I track Flomics Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Flomics Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBarcelona
Employee Range20
Year Founded2018
Last FundingJul 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?